Adverse events of methotrexate treatment in JIA
نویسندگان
چکیده
منابع مشابه
Adverse events of methotrexate treatment in JIA
Background Methotrexate (MTX) which has been used for 20 years in Juvenile Idiopathic Arthritis (JIA) has now become the first-choice, second-line agent for children with polyarticular course JIA. New biologic drugs are used for MTX-failing patients and have been assessed in controlled trials for effectiveness. Safety data of these drugs are slowly and selectively emerging as post-marketing dat...
متن کاملevidence of adverse selection in irans health insurance market
در این تحقیق به مطالعه وجود انتخاب نامساعد(کژ گزینی) در بازار بیمه درمان تکمیلی ایران پرداخته شده است. داده های مورد نیاز توسط پرسشنامه و به روش نمونه گیری خوشه ای جمع آوری شده است. پرسشنامه ها در میان افراد شاغل ساکن شهر تهران توریع شد. در این تحقیق با استفاده از تخمین دو مدل لجستیک و به دست آوردن ضریب همبستگی میان تقاضای بیمه درمان تکمیلی و رخداد خسارت به بررسی موضوع مورد نظر پرداخته شده است....
15 صفحه اولPReS-FINAL-2002: Adverse events during anti-TNF therapy in patients with JIA
Results The follow-up time of the patients was altogether 1516 patient-years (py): 710 for etanercept, 591 for infliximab, 188 for adalimumab, and 27 for other biologic drugs. 216 (62%) patients were female. Median age at onset of JIA was 4.7 years (0.7 to 15.9). Anti-TNF therapy was started at a median age of 10.8 years (2.2 to 19.2). All patients had either received DMARDs prior to anti-TNF o...
متن کاملMethotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan
Methotrexate (MTX), the primary treatment for the articular-type juvenile idiopathic arthritis (JIA), is effective and brings about radiological improvement. Patient compliance is good, and it is recognized that its known side effects, namely, disruption of liver function and induction of pulmonary lesions, are unlikely to be severe at the low MTX doses that are administered. In Japan, MTX was ...
متن کاملEfficacy of Subcutaneous Methotrexate in JIA Patients Who have Failed to Improve with Oral Methotrexate
Methotrexate is the most commonly used disease modifying anti-rheumatic drug (DMARDs) for rheumatoid arthritis1. However, some patients are intolerant to oral MTX despite folate supplementation and some patients do not respond adequately2. The route of administration of MTX in children with juvenile idiopathic arthritis (JIA) is not standardized and varies according to patient’s and treating ph...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Rheumatology
سال: 2011
ISSN: 1546-0096
DOI: 10.1186/1546-0096-9-s1-p203